Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: an updated systematic review and meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Efficacy and safety of PARP inhibitors in the treatment of BRCA-mutated breast cancer: an updated systematic review and meta-analysis of randomized controlled trials

Published:2023-03-04 Issue:3 Volume:16 Page:245-256
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Sun Xiaoyu¹²,Xu Suying¹²,Li Yiming³,Lv Xuemei¹²,Wei Minjie¹²⁴^ORCID,He Miao¹²

Affiliation:

1. Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, Liaoning, China

2. Liaoning Key Laboratory of Molecular Targeted anti-tumor Drug Development and Evaluation; Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors (China Medical University), Ministry of Education, China Medical University, Shenyang, Liaoning, China

3. NHC Key Laboratory of Antibiotic Bioengineering, Laboratory of Oncology, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China

4. Shenyang Kangwei Medical Laboratory Analysis Co. LTD, China Medical University, Liaoning, China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2023.2188193

Reference48 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Cancer statistics, 2022

3. Cancer incidence and mortality in China, 2016

4. Nationwide Trends in Mastectomy for Early-Stage Breast Cancer

5. Breast cancer